Unveiling Henry Schein (HSIC) Q4 Outlook: Wall Street Estimates for Key Metrics

20.02.25 15:15 Uhr

Werte in diesem Artikel
Aktien

64,54 EUR 0,52 EUR 0,81%

Indizes

PKT PKT

17.804,0 PKT -95,0 PKT -0,53%

5.693,3 PKT -18,9 PKT -0,33%

In its upcoming report, Henry Schein (HSIC) is predicted by Wall Street analysts to post quarterly earnings of $1.19 per share, reflecting an increase of 80.3% compared to the same period last year. Revenues are forecasted to be $3.27 billion, representing a year-over-year increase of 8.5%.The consensus EPS estimate for the quarter has been revised 0.7% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.Bearing this in mind, let's now explore the average estimates of specific Henry Schein metrics that are commonly monitored and projected by Wall Street analysts.The average prediction of analysts places 'Net Sales- Healthcare Distribution- Global' at $3.09 billion. The estimate suggests a change of +10% year over year.According to the collective judgment of analysts, 'Net Sales- Healthcare Distribution- Dental- Global' should come in at $1.96 billion. The estimate indicates a change of +9% from the prior-year quarter.The consensus estimate for 'Net Sales- Healthcare Distribution- Medical- Global' stands at $1.12 billion. The estimate points to a change of +11.8% from the year-ago quarter.Analysts' assessment points toward 'Net Sales- Technology and value-added services- Global' reaching $225.31 million. The estimate suggests a change of +6.3% year over year.It is projected by analysts that the 'Geographic Revenue- International- Health Care Distribution' will reach $848.16 million. The estimate indicates a year-over-year change of +9.4%.Analysts expect 'Geographic Revenue- North America- Dental' to come in at $1.15 billion. The estimate suggests a change of +9.5% year over year.Based on the collective assessment of analysts, 'Geographic Revenue- International' should arrive at $877.95 million. The estimate suggests a change of +9.6% year over year.Analysts predict that the 'Geographic Revenue- North America- Medical' will reach $1.10 billion. The estimate indicates a year-over-year change of +12.8%.The combined assessment of analysts suggests that 'Geographic Revenue- International- Medical' will likely reach $29.96 million. The estimate indicates a change of +15.2% from the prior-year quarter.Analysts forecast 'Geographic Revenue- North America- Technology and value-added services' to reach $195.98 million. The estimate indicates a change of +5.4% from the prior-year quarter.The collective assessment of analysts points to an estimated 'Geographic Revenue- International- Technology and value-added services' of $29.80 million. The estimate points to a change of +14.6% from the year-ago quarter.The consensus among analysts is that 'Geographic Revenue- North America- Health Care Distribution' will reach $2.26 billion. The estimate indicates a change of +11.1% from the prior-year quarter.View all Key Company Metrics for Henry Schein here>>>Over the past month, Henry Schein shares have recorded returns of +4.1% versus the Zacks S&P 500 composite's +2.6% change. Based on its Zacks Rank #4 (Sell), HSIC will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Henry Schein, Inc. (HSIC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Henry Schein und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Henry Schein

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Henry Schein

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Henry Schein Inc.

Wer­bung

Analysen zu Henry Schein Inc.

DatumRatingAnalyst
30.05.2019Henry Schein UnderperformWolfe Research
08.11.2018Henry Schein OutperformBarrington Research
04.10.2018Henry Schein OutperformRobert W. Baird & Co. Incorporated
07.08.2018Henry Schein HoldStifel, Nicolaus & Co., Inc.
08.03.2018Henry Schein Equal WeightBarclays Capital
DatumRatingAnalyst
08.11.2018Henry Schein OutperformBarrington Research
04.10.2018Henry Schein OutperformRobert W. Baird & Co. Incorporated
07.08.2018Henry Schein HoldStifel, Nicolaus & Co., Inc.
08.12.2017Henry Schein BuyDeutsche Bank AG
07.11.2017Henry Schein HoldStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
08.03.2018Henry Schein Equal WeightBarclays Capital
07.11.2017Henry Schein Sector PerformRBC Capital Markets
19.09.2017Henry Schein Sector PerformRBC Capital Markets
15.03.2017Henry Schein HoldDeutsche Bank AG
14.10.2016Henry Schein NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
30.05.2019Henry Schein UnderperformWolfe Research
10.03.2005Update Henry Schein Inc.: SellBanc of America Sec.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Henry Schein Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen